drugset / Trial / NCT04658173

Efficacy and Safety Profile of Remimazolam-alfentanil Combination for ERCP Sedation

NCT04658173

Unknown 1000 enrolled Tianjin Nankai Hospital
RandomizedParallel-groupSingle-blindOther

Summary

Moderate to deep levels of sedation and analgesia are required for ERCP. Propofol-based sedation is simple, easy to use, and effective, but is not without cardiovascular and respiratory adverse effects. The combination of remimazolam and alfentanil has shown promising results for sedation in other similar scenarios. The aim of this study was to compare the efficacy and safety of a standard propofol-alfentanil regimen with a remimazolam-alfentanil combination.

Timeline

Start
2020-12-22
Primary completion
2022-10-01
Completion
2023-10-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alfentanil Other / unclassified 1 ug/kg
Comparator Propofol Small molecule 2 mg/kg Intravenous
Comparator Propofol Small molecule 6 mg/kg Intravenous
Subject Remimazolam Small molecule 0.2 mg/kg Intravenous
Subject Remimazolam Small molecule 1 mg/kg Intravenous

Indications

No indication recorded.